Trial Profile
Immunogenicity and Safety Study of GSK Biologicals' Monovalent Pandemic H5N1 Vaccine 1557484A in Adults Aged 18 - 64 Years.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2024
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 21 Dec 2011 Actual initiation date (Aug 2011) added as reported by ClinicalTrials.gov.
- 21 Dec 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.